How much do ex-US revenues make a difference for pharmaceutical investment returns?
Publication: Journal of Comparative Effectiveness Research
Formats available
You can view the full content in the following formats:
References
1.
Ramagopalan SV, Bacon C, Walker M, Ryan ML. The need to consider market access for pharmaceutical investment decisions: a primer. J. Comp. Eff. Res. 14(5), e250036 (2025).
2.
Xie RZ, Cameron T, Kolchinsky P. The impact of the Inflation Reduction Act on investment in innovative medicines: a project-level analysis. Ther. Innov. Regul. Sci. 59(3), 409–417 (2025).
3.
Ramagopalan SV, Pannelay AJ. Access in all areas? A round up of developments in market access and health technology assessment: part 9. J. Comp. Eff. Res. e250120 (2025).
4.
Ramagopalan SV, Diaz J, Mitchell G, Garrison LP Jr, Kolchinsky P. Is the price right? Paying for value today to get more value tomorrow. BMC Med. 22(1), 45 (2024).
5.
DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016).
6.
Zheng H, Patterson JA, Campbell JD. The Inflation Reduction Act and drug development: potential early signals of impact on post-approval clinical trials. Ther. Innov. Regul. Sci. 59(4), 781–789 (2025).
7.
Schulthess DG, O'Loughlin G, Askeland M, Gassull D, Bowen HP. The Inflation Reduction Act's impact upon early-stage venture capital investments. Ther. Innov. Regul. Sci. 59(4), 769–780 (2025).
Information & Authors
Information
Published In
Copyright
© 2025 The authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 25 July 2025
Accepted: 8 August 2025
Published online: 2 September 2025
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
How much do ex-US revenues make a difference for pharmaceutical investment returns?. (2025) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2025-0121
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Sreeram V Ramagopalan, Annie Jullien Pannelay, Access in all areas? A round-up of developments in market access and health technology assessment: part 12, Journal of Comparative Effectiveness Research, 10.57264/cer-2025-0208, 15, 2, (2026).
- Sreeram V Ramagopalan, Michael L Ryan, Most-Favored-Nation pricing meets Joint Clinical Assessment: early evidence of compounding pressure on European drug launches, Journal of Comparative Effectiveness Research, 10.57264/cer-2026-0110, 0, 0, (undefined).